Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice

Neurobiology of Disease

Volumn 11, Issue 3, 2002, Pages 425-433

  Weiss, C ^a   Venkatasubramanian, P N ^b   Aguado, A S ^a   Power, J M ^c   Tom, B C ^b   Li, L ^b   Chen, K S ^d   Disterhoft, J F ^a   Wyrwicz, A M ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Center for MR Research   (United States)

^c Biology and Environment   (Australia)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Amyloid; Eyeblink conditioning; Hippocampus; MR imaging; Neurodegeneration; Transgenic mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN SIZE; CONTROLLED STUDY; DISEASE COURSE; EYELID REFLEX; HETEROZYGOSITY; HIPPOCAMPUS; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TISSUE SECTION; TRANSGENIC MOUSE; WILD TYPE;

EID: 0344838640     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2002.0555     Document Type: Article

References (41)

1. Bahro M., Schreurs B. G., Sunderland T., Molchan S. E. The effects of scopolamine, lorazepam, and glycopyrrolate on classical conditioning of the human eyeblink response. Psychopharmacology (Berlin). 122:1995;395-400.
2. Bales K. R., Verina T., Cummins D. J., Du Y., Dodel R. C., Saura J., Fishman C. E., DeLong C. A., Piccardo P., Petegnief V., Ghetti B., Paul S. M. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:1999;15233-15238.
3. Chapman P. F., White G. L., Jones M. W., Cooper-Blacketer D., Marshall V. J., Irizarry M., Younkin L., Good M. A., Bliss T. V., Hyman B. T., Younkin S. G., Hsiao K. K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2:1999;271-276.
4. Chen L., Bao S., Thompson R. F. Bilateral lesions of the interpositus nucleus completely prevent eyeblink conditioning in Purkinje cell-degeneration mutant mice. Behav. Neurosci. 113:1999;204-210.
5. Chen G., Chen K. S., Knox J., Inglis J., Bernard A., Martin S. J., Justice A., McConlogue L., Games D., Freedman S. B., Morris R. G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979.
6. Christie R. H., Bacskai B. J., Zipfel W. R., Williams R. M., Kajdasz S. T., Webb W. W., Hyman B. T. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J. Neurosci. 21:2001;858-864.
7. De Toledo-Morrell L., Sullivan M. P., Morrell F., Wilson R. S., Bennett D. A., Spencer S. Alzheimer's disease: In vivo detection of differential vulnerability of brain regions. Neurobiol. Aging. 18:1997;463-468.
8. Disterhoft J. F., Thompson L. T., Weiss C., Moyer J. R. Jr., Van der Zee E., Carrillo M., Kronforst-Collins M., Power J. The calcium hypothesis for Alzheimer's Disease: Insights from animal and human studies. Neurosci. Res. Communications. 17:1995;121-131.
9. Dodart J-C., Mathis C., Bales K. R., Paul S. M., Ungerer A. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci. Lett. 277:1999a;49-52.
10. Dodart J-C., Mathis C., Saura J., Bales K. R., Paul S. M., Ungerer A. Neuroanatomical abnormalities in behaviorally characterized APP(V717F) transgenic mice. Neurobiol. Dis. 7:2000;71-85.
11. Dodart J-C., Meziane H., Mathis C., Bales K. R., Paul S. M., Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav. Neurosci. 113:1999b;982-990.
12. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527.
13. Gonzalez-Lima F., Berndt J. D., Valla J. E., Games D., Reiman E. M. Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease. NeuroReport. 12:2001;2375-2379.
14. Harvey J. A., Gormezano I., Cool-Hauser V. A. Effects of scopolamine and methylscopolamine on classical conditioning of the rabbit nictitating membrane response. J. Pharmacol. Exp. Ther. 225:1983;42-49.
15. Hsia A. Y., Masliah E., McConlogue L., Yu G. Q., Tatsuno G., Hu K., Kholodenko D., Malenka R. C., Nicoll R. A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA. 96:1996;3228-3233.
16. Hsiao K. K., Borchelt D. R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 15:1995;1203-1218.
17. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
18. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., Chishti M. A., Horne P., Heslin D., French J., Mount H. T., Nixon R. A, Mercken M., Bergeron C., Fraser P. E., St. George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
19. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
20. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 16:1996;5795-5811.
21. Moore J. W., Goodell N. A., Solomon P. R. Central cholinergic blockage by scopolamine and habituation, classical conditioning, and latent inhibition of the rabbit's nictitating membrane response. Physiol. Psychol. 4:1976;395-399.
22. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G. W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
23. Moser M. B., Moser E. I. Functional differentiation in the hippocampus. Hippocampus. 8:1998;608-619.
24. Moyer J. R., Deyo R. A., Disterhoft J. F. Hippocampectomy disrupts trace eye-blink conditioning in rabbits. Behav. Neurosci. 104:1990;243-252.
25. Oh M. M., Gamelli A. E., Wu W. W., Sametsky E. A., Disterhoft J. F. Morris watermaze learning enhances excitability of CA1 pyramidal neurons. Soc. Neurosci. Abs. 27:2001.
26. Rockenstein E. M., McConlogue L., Tan H., Power M., Masliah E., Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J. Biol. Chem. 270:1995;28257-28267.
27. Routtenberg A., Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Measuring memory in a mouse model of Alzheimer's disease. Science. 277:1997;839-841.
28. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
29. Schuff N., Amend D., Ezekiel F., Steinman S. K., Tanabe J., Norman D., Jagust W., Kramer J. H., Mastrianni J. A., Fein G., Weiner M. W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology. 49:1997;1513-1521.
30. Skovronsky D. M., Zhang B., Kung M. P., Kung H. F., Trojanowski J. Q., Lee V. M. In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;7609-7614.
31. Solomon P. R., Brett M., Groccia-Ellison M. E., Oyler C., Tomasi M., Pendlebury W. W. Classical conditioning in patients with Alzheimer's disease: A multiday study. Psychol. Aging. 10:1995;248-254.
32. Solomon P. R., Groccia-Ellison M. E., Flynn D., Mirak J., Edwards K. R., Dunehew A., Stanton M. E. Disruption of human eyeblink conditioning after central cholinergic blockade with scopolamine. Behav. Neurosci. 107:1993;271-279.
33. Solomon P. R., Solomon S. D., Schaaf E. V., Perry H. E. Altered activity in the hippocampus is more detrimental to classical conditioning than removing the structure. Science. 220:1983;329-331.
34. Solomon P. R., Vander Schaaf E. R., Thompson R. F., Weisz D. J. Hippocampus and trace conditioning of the rabbit's classically conditioned nictitating membrane response. Behav. Neurosci. 100:1986;729-744.
35. Thompson R. F. Neural mechanisms of classical conditioning in mammals. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 329:1990;161-170.
36. Weiss C., Bouwmeester H., Power J. M., Disterhoft J. F. Hippocampal lesions prevent trace eyeblink conditioning in the freely moving rat. Behav. Brain Res. 99:1999a;123-132.
37. Weiss C., Knuttinen M-G., Power J. M., Patel R. I., O'Connor M. S., Disterhoft J. F. Trace eyeblink conditioning in the freely moving rat: Optimizing the conditioning parameters. Behav. Neurosci. 113:1999b;1100-1105.
38. Weiss C., Thompson R. F. Delayed acquisition of eyeblink conditioning in aged F1 hybrid (Fischer-344 * Brown Norway) rats. Neurobiol. Aging. 13:1992;319-323.
39. Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G., Ashe K. H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:2002;1858-1867.
40. Woodruff-Pak D. S., Finkbiner R. G., Sasse D. K. Eyeblink conditioning discriminates Alzheimer's patients from non-demented aged. NeuroReport. 1:1990;45-48.
41. Woodruff-Pak D. S., Papka M., Romano S., Li Y. T. Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia. Neurobiol. Aging. 4:1996;505-512.